Ufa Eye Research Institute
90 Pushkin st./ 14 Aurora st., Ufa, Russia, 450008
Call Center
+7 (347) 286-5303 eye@bashgmu.ru, eye@anrb.ru
  2. History of the Institute
  3. News
  4. News: Conference
  5. Participation in the seminar devoted to the study of LUMINOUS in Russia, 29 – 30 October 2015 (Irkutsk).

Participation in the seminar devoted to the study of LUMINOUS in Russia, 29 – 30 October 2015 (Irkutsk).

bc33234a9d34e004abe350190ce01dd8.JPG
261ee6379563af6b1ab2f47717bd7442.JPG
d4fa6a5f6fcd239b59503798fb9179e1.jpg
2 November 2015, Monday 00:00 Просмотров: 572

Д.м.н. Будзинская М. В. (г. Москва) с докладом.JPG29 – 30 October in Irkutsk took place the seminar devoted to the study of LUMINOUS in Russia. LUMINOUS is an international multicenter study aimed to study the long-term effectiveness and safety of clinical use of the drug Ranibizumab.

The representative of the Ufa research Institute of eye diseases in this seminar was the senior researcher of the Department vitreoretinaleand laser surgery, PhD Gil'manshin I Tr
The main purpose of the event was summing up the preliminary results of a 5–year study, completion of which is planned on 21 March 2016.
The workshop was attended by researchers from more than 20 cities of Russia. Made presentations to the heads of agencies and units involved in the programme.

This study involved 43 countries, 494 researchx center, 30514 patients. Russia ranks 6th in the number of participating patients (after the UK, Australia, Canada, China, Japan) – 1,320 20 researchx centers.

Special attention was paid to the peculiaritiesthe research results obtained in Russia profile Russian patients participating in the study. A number of reports were devoted to the proper conduct of the Protocol of this study, i.e. to meet the conditions of good clinical research andth practice (GCP). Discuss some organizational issues.

In the future, will take place on 2 and 3 phases of the test centres accredited to conduct clinical research.

Especially interesting was the report of the medical Director of the company “Novartis Farma” is a relatively new medical developments of the company.